Limits...
Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification.

Huang ZH, Sun ZY, Gao Y, Chen PG, Liu YF, Chen YX, Li YM - Vaccines (Basel) (2014)

Bottom Line: However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements.To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated.In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China. huangzh05@mails.tsinghua.edu.cn.

ABSTRACT
Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

No MeSH data available.


Guo’s vaccine consisting of the carbohydrate antigen and the TLR4 agonist [31].
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494217&req=5

vaccines-02-00549-f003: Guo’s vaccine consisting of the carbohydrate antigen and the TLR4 agonist [31].

Mentions: Guo and co-workers designed a vaccine consisting of a GM3 carbohydrate antigen and monophosphoryl lipid A, an agonist of TLR4 from the cell wall of Gram-negative bacteria (Figure 3) [31,32].


Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification.

Huang ZH, Sun ZY, Gao Y, Chen PG, Liu YF, Chen YX, Li YM - Vaccines (Basel) (2014)

Guo’s vaccine consisting of the carbohydrate antigen and the TLR4 agonist [31].
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494217&req=5

vaccines-02-00549-f003: Guo’s vaccine consisting of the carbohydrate antigen and the TLR4 agonist [31].
Mentions: Guo and co-workers designed a vaccine consisting of a GM3 carbohydrate antigen and monophosphoryl lipid A, an agonist of TLR4 from the cell wall of Gram-negative bacteria (Figure 3) [31,32].

Bottom Line: However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements.To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated.In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China. huangzh05@mails.tsinghua.edu.cn.

ABSTRACT
Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

No MeSH data available.